Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

November 25, 2015

Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.

Previous Article
Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma
Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approv...

Next Article
Health insurance coverage for transgender people is cost-effective, study finds
Health insurance coverage for transgender people is cost-effective, study finds

A new analysis led by the Johns Hopkins Bloomberg School of Public Health suggests that while most U.S. hea...